Jorda Radek
Journals
        A patent review of cyclin-dependent kinase 7 (CDK7) inhibitors (2018-2022).        
                  Expert Opinion on Therapeutic Patents.                
                  2023,
                
                              33(2),
                  
                              67-87,
                          
                  ISSN: 1354-3776,
                
                
                              PMID: 36975020,                          
                
                          
        
      
    
        Anticancer effect of zanubrutinib in HER2-positive breast cancer cell lines.        
                  Investigational New Drugs.                
                  2023,
                
                              41(2),
                  
                              210-219,
                          
                  ISSN: 0167-6997,
                
                
                              PMID: 36913160,                          
                
                          
        
      
     
         
               
              